Qi Shuo, Zhou Lei, Liu Weinan, Shen Lian, Yao Yuping, Tian Bingzhang, Liu Changjun, Cheng Wei, Chen Kang
Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
Front Immunol. 2025 Jun 11;16:1605048. doi: 10.3389/fimmu.2025.1605048. eCollection 2025.
Early-stage hepatocellular carcinoma (HCC) poses a significant challenge due to its poor prognosis, necessitating advancements in diagnostic and therapeutic strategies. The integration of near-infrared photoacoustic (PA) imaging with magnetic resonance (MR) imaging offers enhanced temporal and spatial resolution, exceptional optical contrast, and profound tissue penetration, positioning this combination as a highly promising technique for accurate and sensitive HCC diagnosis.
In this study, we developed a multifunctional and highly biocompatible nanoplatform, designated as ICG/Mn-PDA-PEG-CXCR4 (IMPP-c). This nanoplatform is designed to diagnose and treat early-stage HCC through PA/MR imaging-guided noninvasive photothermal therapy (PTT) and photodynamic therapy (PDT).
Both and experiments demonstrated enhanced accumulation of IMPP-c nanoparticles (NPs) within HCC. Notably, the dual-modal PA/MR imaging facilitated by IMPP-c achieved high resolution and substantial deep tissue penetration, enabling precise localization of early orthotopic small hepatocellular carcinoma (SHCC) lesions. tumor phototherapy experiments, guided by PA/MR imaging, revealed that SHCC was completely eradicated through noninvasive PTT/PDT without recurrence. Additionally, the metabolism of IMPP-c NPs was observed in major organs throughout the treatment process, confirming its reliable biocompatibility.
This study introduces a novel method for diagnosing and implementing non-invasive therapeutic interventions in early HCC using nanoparticle systems such as IMPP-c, paving the way for potential future clinical applications.
早期肝细胞癌（HCC）因其预后较差而构成重大挑战，因此需要改进诊断和治疗策略。近红外光声（PA）成像与磁共振（MR）成像的结合提供了更高的时间和空间分辨率、出色的光学对比度以及深层组织穿透能力，使这种组合成为用于准确、灵敏诊断HCC的极具前景的技术。
在本研究中，我们开发了一种多功能且具有高度生物相容性的纳米平台，命名为ICG/Mn-PDA-PEG-CXCR4（IMPP-c）。该纳米平台旨在通过PA/MR成像引导的非侵入性光热疗法（PTT）和光动力疗法（PDT）来诊断和治疗早期HCC。
体外和体内实验均表明IMPP-c纳米颗粒（NPs）在HCC内的蓄积增强。值得注意的是，由IMPP-c实现的双模态PA/MR成像具有高分辨率和显著的深层组织穿透能力，能够对早期原位小肝细胞癌（SHCC）病变进行精确定位。在PA/MR成像引导下的肿瘤光疗实验显示，通过非侵入性PTT/PDT可完全根除SHCC且无复发。此外，在整个治疗过程中观察到IMPP-c NPs在主要器官中的代谢情况，证实了其可靠的生物相容性。
本研究介绍了一种使用诸如IMPP-c之类的纳米颗粒系统对早期HCC进行诊断和实施非侵入性治疗干预的新方法，为未来潜在的临床应用铺平了道路。
